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Summary
The current coronavirus disease (COVID‐19) pandemic caused by novel severe
acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has a male bias in severity
and mortality. This is consistent with previous coronavirus pandemics such as SARS‐
CoV and MERS‐CoV, and viral infections in general. Here, we discuss the sex‐dis-
aggregated epidemiological data for COVID‐19 and highlight underlying differences
that may explain the sexual dimorphism to help inform risk stratification strategies
and therapeutic options.
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1 | INTRODUCTION
The current coronavirus disease (COVID‐19) pandemic, caused by
the novel severe acute respiratory syndrome coronavirus 2 (SARS‐
CoV‐2), has overwhelmed healthcare systems around the world
bringing significant morbidity and mortality. The World Health Or-
ganization has declared it to be a public health emergency of inter-
national concern. As of 31 October 2020, there have been >45
million confirmed cases reported worldwide, with deaths exceeding
1.18 million and still rising.1 Whilst most reported cases of COVID‐19
experience mild to moderate symptoms including fever, persistent
cough, loss of taste and smell, or dyspnoea, about 15% of infected
adults develop severe pneumonia requiring oxygen supplementation
via invasive mechanical ventilators. Among these, 5% progress to a
critical stage with acute respiratory distress syndrome (ARDS),
hypoxic respiratory failure and multi‐organ failure, that necessitates
mechanical ventilation.2,3
Epidemiological data from previous coronavirus epidemics‐
SARS‐CoV (2002) and Middle Eastern respiratory syndrome coro-
navirus (MERS, 2012) highlighted differences in their manifestation
based on sex, with men being consistently more severely affected
than women.4–7 Early reports of COVID‐19 also suggest a sex
imbalance, with men at a higher risk of more severe disease and
increased case fatality ratio (CFR).3,8 Publicly available sex‐dis-
aggregated data from several governments compiled by the Global
Health 50/50 research initiative also show, despite similar numbers
of COVID‐19 cases in men and women, an increased fatality rate in
men as outlined in Figure 1, with the male:female ratio of deaths
among confirmed cases ranging from 1.0 in Pakistan and Canada to
2.1 in Wales.9 In addition to fatality, hospitalizations and admissions
to intensive care units (ICU) can serve as a measure of disease
severity. A review of epidemiological data by Gebhard et al. (2020)
comprising confirmed COVID‐19 cases in several countries including
China, Italy and Spain show that there were 50% more men requiring
hospitalization compared to women, with ICU admission being three
to fourfold higher.10,11 A meta‐analysis of 15 independent studies
that recorded sex disaggregated patient outcomes found men had an
odds ratio of 1.31 to develop a severe COVID‐19 infection compared
to women.12 United States of America has the highest number of
COVID‐19 cases to date and early reports by the Centers for Disease
Control and Prevention (CDC) across 14 states also observed higher
hospitalization rates for men.13 A recent count by Global Health 50/
50 also confirms this indication of sex imbalance in disease severity
across several countries (Figure 2).9 There are, however, some limi-
tations to this data set particularly as the interaction between age
and sex remains unexplored.
On investigating the magnitude of differences in survival for both
sexes in Europe across different age groups, Ahrenfeldt et al. (2020)
reported that the relative risk of dying from COVID‐19 is consis-
tently elevated in men across all age groups with the differences
increasing until the age range 60–69 years.14 Thereafter, the sex
difference in survival decreases and was at its lowest for ages 80+.14
A study comprising of 227,000 confirmed cases of COVID‐19 pooled
from Italy, Germany, Spain and Switzerland also suggested that the
sex difference in fatality is most pronounced in the ages 50–59, and
decreases subsequently with increasing age.10 Interestingly, as per
the Global Health 50/50 data, numbers of confirmed cases are similar
for men and women, suggesting equal infection rates.9 More detailed
reports on incidence rates from Switzerland and Germany also sug-
gest similar proportions of COVID‐19 cases in men and women at all
age groups (Figure 3), thereby highlighting the worsened prognosis in
infected males compared to females.15,16
To some extent, sex difference in COVID‐19 expands to affect
the male reproductive system either directly or indirectly as some
articles suggest.17
As vaccines and other treatment modalities are researched and
developed in attempt to contain the recurrent surges in infections for
this pandemic, better understanding of the sex imbalance and its
underlying biology can help inform public health strategies for testing
and intervention by stratifying groups at high risk for severe disease;
and help improve therapeutic options by allowing gender‐specific
targeted treatments. Herein, we discuss several factors that may
contribute to the sex differences observed in COVID‐19 patients,
including possible biological reasons, contributions of comorbidities,
and highlight any role that gender may play.
2 | SEX DIFFERENCES IN VIRAL ENTRY
Angiotensin converting enzyme‐2 (ACE2) catalyses the conversion of
angiotensin‐II to angiotensin (1–7), and plays a vital role in homeo-
stasis of blood pressure, inflammatory responses and blood coagu-
lation.18 ACE2 is expressed in a range of tissues including nasal and
respiratory epithelial cells, blood vessels and kidneys.19–22 As with
SARS‐CoV, membrane‐bound ACE2 serves as a receptor for the
SARS‐CoV‐2 spike (S) glycoprotein, facilitating its attachment to the
cell surface and subsequent entry.23
The expression levels of ACE2 correlate with the risk of
COVID‐19 severity, with children who have lower ACE2 expression
in their nasal epithelium having a lower risk compared to adults.24
However, evidence regarding a sex disparity in ACE2 expression is
unclear. A phenomenon, termed X chromosome inactivation, is an
epigenetic process that silences one of the two X‐chromosomes in
females to maintain balance in gene expression dosage.25 The ACE2
gene is located on the X chromosome, and is thought to have higher
levels of expression in females. This is because it has been reported
that ACE2, frequently ‘escapes’ inactivation that occurs to balance
expression dosage between the sexes, has an uncharacteristic het-
erogeneous pattern of male‐female expression based on the tis-
sues.25 In pre‐clinical studies, ACE2 expression has been reported to
be higher in female rat lungs and kidneys.26,27 Conversely, oestrogen
downregulates the expression of ACE2 in vitro and in gonadectom-
ised female mice.28,29 In human tissues, studies have suggested no
significant difference in the expression of ACE2 for both sexes in
respiratory tissues,30–32 and in circulation are more elevated for male
patients with comorbidities such as cardiovascular diseases.33 Taken
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F I GUR E 1 Sex‐disaggregated data of confirmed COVID‐19 cases and deaths from countries with >10,000 cases. Cases and deaths are
only reported where sex‐disaggregated data is available, and not total cases. Data from Global Health 50/50 COVID‐19 data tracker as of 31st
October 2020.9
ALWANI ET AL. - 3
F I GUR E 2 Disease severity is higher in males as measured by hospitalizations and ICU admissions. Graphs reproduced from Global Health
50/50 COVID‐19 data tracker.9
F I GUR E 3 Reported COVID‐19 cases in Germany by age group and gender (n = 254,549) (Data accessed on10/09/2020, from https://
www.rki.de/EN/Content/infections/epidemiology/outbreaks/COVID‐19/Situationsberichte_Tab.html)
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together, the levels of ACE2 expression varies based on tissues and
underlying comorbidities and therefore it may not be a strong pre-
dictor for disease severity isolation.
Transmembrane protease serine 2 (TMPRSS2) is also vital for viral
entry, following its binding to ACE2, by priming the viral S protein (by
proteolytic cleavage) and mediating fusion of viral and cell mem-
branes.34,35 Indeed, in an in vitro model, inhibiting TMPRSS2 activity
partially inhibited the entry of SARS‐CoV‐2 into lung epithelial cells.34
In vivo, TMPRSS2 deficient mice demonstrated reduced weight loss
and inflammatory response in the lungs following SARS‐CoV and
MERS‐CoV infections, suggesting decreased severity.36
Interestingly, a study by Asselta et al. (2020), which compared
the expression of TMPRSS2 in the two sexes from a large Italian
cohort observed a higher expression of TMPRSS2 in bronchial
epithelial cells in the males compared to females.31 TMPRSS2 plays a
pivotal role in the development and progression of prostate cancer
via gene fusion, and is strongly upregulated in response to andro-
gens.37,38 These data suggests that TMPRSS2 expression might
mediate the sex disparity observed in severity of COVID‐19. How-
ever, it is unclear if androgen signalling can modulate TMPRSS2
expression in respiratory tissues, and whether low level of androgens
present in women can maintain TMPRSS2 expression in respiratory
tissues. Further research is therefore required to determine if there
is a sex‐biased expression and/or regulation of ACE2 and TMPRSS2
that confers increased severity COVID‐19 in males compared to fe-
males. This is especially topical with current treatment strategies
targeting these proteins.39
3 | SEX DIFFERENCES IN IMMUNE RESPONSES
Sex‐based differences in immune responses have been reported for
adults and children,40 suggesting an influence of both the sex chro-
mosome and hormones on the immune system. The X chromosome
encodes several genes that regulate immune function and is funda-
mental in shaping sex‐specific immune responses.41 As mentioned
previously, X chromosome inactivation silences one of the two X‐
chromosomes in females to maintain balance in gene expression
dosage. This process leads to 50% cells in females having the
maternal X chromosome inactivated, whilst the paternal X chromo-
some is inactivated in the rest, a phenomenon termed as ‘cell
mosaicism’.42 This provides females with a greater plasticity and
adaptability in response to infections, especially in case of X‐linked
mutations by expressing the corresponding wild‐type allele on the
other X chromosome.43 Furthermore, some immune related genes
are partially reactivated in female lymphocytes to confer enhanced
immunity to infectious diseases.44
3.1 | Role of innate immunity
The sexual dimorphism in immune responses to vaccines and viral
infections has been well documented. There is compelling evidence
showing that females differ in their innate recognition and response
to viral infections, and mount a greater inflammatory and humoral
immune response.45,46 As a result, both the prevalence and intensity
of viral infections are often lower for females.47–49 Toll‐like receptor
are a class of innate immune pattern recognition receptors that
recognize bacterial or viral pathogen‐associated molecular patterns.
TLR7 is an endosomal receptor expressed constitutively in plasma-
cytoid dendritic cells (pDCs) and B‐cells,50 and is capable of detecting
single‐stranded ribonucleic acids from viruses, including coronavi-
rus.51 Upon recognition of viral infection, TLR7 triggers an antiviral
type I interferon (IFN) response which serves to control viral repli-
cation and activate an adaptive immune response to clear the
infection.52,53
TLR7 is encoded on the X‐chromosome, and is one of the 23% of
the X‐linked genes that exhibit incomplete inactivation resulting in
increased dosage in females.54 Using single‐cell analyses, Souris et al.
(2018) demonstrated that TLR7 is transcribed on both X chromo-
somes in pDCs and B‐cells, and correlates with higher TLR7 protein
expression in female leucocyte populations.55 This disparity in TLR7
expression enhances innate immune responses to viruses,56 and may
confer females an advantage as observed with COVID‐19. Indeed,
some early COVID‐19 case‐reports suggest a link between loss‐of‐
function TLR7 mutations and increased disease severity in young
patients.57
Interferon α and β (IFNα and IFNβ) are the primary effector
cytokines of the type I IFN response downstream of TLR activation,
and critical players of the immune system, linking innate to adaptive
immunity.58 IFNα/β production by pDCs is primarily mediated
through the stimulation of TLR7 during viral infection, and is essen-
tial for the maturation of DCs to effective antigen‐presenting cells
with increased ability to activate T cells.59–61 Several studies have
shown that pDCs from females produce more IFNα/β than males,
following TLR7 activation by viral RNA.56,62,63 In a study cohort of 50
COVID‐19 patients with mild/moderate to critical severity, Hadjadj
et al. (2020) employed an integral approach by conducting in‐depth
phenotypical analysis of immune cells, whole‐blood transcriptomics
and cytokine measurements.64 They observed that the severity of the
disease characterized by persistent viral load in the blood and
exacerbated inflammation associated with highly impaired type I IFN
response, with very low levels of IFNα and no IFNβ.64 Taken
together, this suggests that females may have a better prognosis
following SARS‐CoV‐2 infection partly because of their heightened
type I IFN response, and enhancing type I IFN response could serve
as a therapeutic possibility for COVID‐19.
Genetically, a British gene‐wide association study attained in
critically ill COVID‐19 patients, revealed loss‐of‐function mutation in
the one of the responsible genes for IFNα and IFNβ expression called
IFNAR2, explaining the lower interferons level in the critically ill
patients specifically.65
Whilst the initial immune response against the pathogen is vital
to protect the host, an overactivation of the response that results
overproduction in pro‐inflammatory cytokines causes immunopa-
thology leading to multiple organ failure and ultimately death. In a
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recent study, Liu et al. (2020) evaluated the severest multi‐organ
dysfunctions during entire hospitalization between males and fe-
males which helps predict in‐hospital death.66 They observed that
whilst multiple key factors that characterize a ‘cytokine storm’ were
elevated (pro‐inflammatory cytokines such as TNFα, IL6 and IL8) in
females during the acute infection phase, these mediators were lower
when measured over the whole duration of hospitalization, possibly
offering a survival advantage. However, when the infection persisted,
the heightened immune response in females led to more ferocious
organ injuries and their survival advantage diminished.66
3.2 | Role of adaptive immunity
In general, females mount a much stronger cellular and humoral
immune response post viral infections,67–69 and vaccinations.70
T cells play an integral role in cell mediated immune response, with
CD4+ T cells orchestrating the B cell response for antibody pro-
duction and CD8+ T cells responsible for the killing of infected cells
and reducing viral burden. Akin to SARS‐CoV,71 several reports
following SARS‐CoV‐2 infection describe a correlation of COVID‐19
severity with lymphopenia, and drastically reduced circulating CD4
+ and CD8+ T cells.72–74 In a longitudinal study comparing immune
responses between sexes, Takahashi et al. (2020) observed that
whilst T cell lymphopenia occurred in both sexes, female patients
mounted a more robust T cell activation, particularly for CD8+
T cells.75 A balance between the CD4+ pro‐inflammatory T helper
type 1 (Th1) and anti‐inflammatory type 2 (Th2) subtypes is vital for
regulating the immune response and resolving of the infection
without damaging host tissue. Studies with SARS‐CoV and MERS‐
CoV describe upregulation of Th1 cytokines, dysregulating the Th1/
Th2 balance.76,77 Sexual dimorphism in Th1 and Th2 responses
based on the stages of infection have been reported previously,78
and further research is needed to elucidate if it plays a role in
COVID‐19.
T follicular helper (Tfh) cells, are a subset of CD4+ T cells,
responsible for the differentiation of B cells into plasma cells and
memory B cells. In patients with severe disease particularly, the
improved outcomes for females can also be attributed to higher
levels of circulating IgG antibodies against SARS‐CoV‐2 as observed
by Zeng et al. (2020).79 Furthermore, in a comprehensive analysis of
sex differences in B‐cell gene expression, Fan et al. (2014) found over
350 differentially expressed genes between males and females.80
These include upregulation of immune response genes such as Cav1,
CXCR3, and downregulation of inflammatory genes such as IL7R and
DDX3Y, and may account for some of the observed sex bias observed
in COVID‐19.80 Taken together, the reports suggest that the immune
landscape in COVID‐19 is considerably different between the two
sexes and may contribute to the higher susceptibility observed in
males. These, along with genes such as ACE2 and TLR7 that escape
inactivation, cause a gene dosage imbalance between the sexes and
may contribute to the immune disparity.
3.3 | Role of sex hormones
The role of sex hormones in regulating immunity is well character-
ized, and is likely to play a role in differences in the severity of
COVID‐19 between males and females. Oestrogen has a dual effect
based on its levels. At low doses similar to those in post‐menopausal
women, oestrogen is immuno‐stimulatory and induces differentiation
of inflammatory dendritic cells, higher production of IL‐4 and IFNα,
and an increased Th1 type and cell mediated responses. Conversely,
at higher doses observed in premenopausal women, oestrogen pro-
motes anti‐inflammatory Th2 responses and is inhibitory to the
pro‐inflammatory innate immune response.78,81–83 Indeed, Chan-
nappanavar et al. (2017) demonstrated that mortality in female mice
infected with SARS‐CoV increased following ovariectomy or expo-
sure to oestrogen receptor antagonist suggesting a protective role of
oestrogen receptor signalling.84 A similar protective effect of oes-
trogen has also been suggested in a recent pre‐print study which
investigated the association of oestrogen with severity of COVID‐19
symptoms.85 The study observed a higher risk in post‐menopausal
women; and in younger women who did not take the combined oral
contraceptive pill (COCP) compared to those of similar aged women
taking COCP.85 A similar observation was reported by Ding et al.
(2020), who showed that post‐menopausal women were at a greater
risk of hospitalization, and that oestrogen levels had a protective
effect against disease severity.86 This protective effect of oestrogen
was attributed to reduced levels of inflammatory IL‐6, IL‐8 and
TNFα.86
Early reports from China, Germany and Italy have suggested that
low testosterone levels strongly correlate with disease severity and
the need for intensive care in male patients.87,88 Testosterone im-
munosuppresses,89 by reducing the production of pro‐inflammatory
IL‐6, IL‐1β and TNFα via inhibition of the NF‐κB pathway.90 In fact,
IL‐6 is a key mediator of disease progression to ARDS in COVID‐19,
and a clinical trial of tocilizumab, an IL‐6 receptor blocker, is
approved in China for patients with severe disease.91 This suggests
that the role of testosterone on the immune response to SARS‐
CoV‐2 may be beneficial to patient outcomes potentially suppressing
uncontrolled inflammatory responses. Conversely, men with higher
levels of testosterone have weakened immunity and produce the
lowest antibody responses to annual flu vaccinations.92
Low serum testosterone can increase the expression of ACE‐2
receptors and TMPRSS2, with patients reportedly developing severe
manifestations of COVID‐19 infections which require assisted
ventilation as a result of the upregulation of ACE‐2 receptors in
lower respiratory cells increasing risk of lung damage and respiratory
muscle catabolism.93,94 Reduced testosterone in men can also inhibit
pulmonary endothelial cell function as SARS‐CoV‐2 reduces ACE‐2
concentrations by binding and increasing angiotensin‐II while
lowering angiotensin 1–7. As a result of this process superoxide
species become increased, leading to oxidative stress induced
endothelial cell dysfunction and localised inflammation.95,96 Conse-
quently, von Willebrand factor expression can increase and
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development of thrombosis in the alveolar capillaries, a precursor of
ARDS, ensues.97–99
Testosterone levels are known to decline following onset of
disease, and in particular, during infections with low testosterone
often considered a marker of ill health.100 This may have evolu-
tionary origins to move energy away from high‐energy consuming
anabolic processes to allow instead most energy for strengthening
the immune response. It has been suggested that COVID‐19 might
deteriorate serum testosterone level in SARS‐CoV‐2 infected male
patients and that a lower pre‐infection testosterone may significantly
increase the risk of ICU transfer and mortality.101 The authors
additionally propose possible improvement in clinical outcomes with
the testosterone treatment in SARS‐CoV‐2 infected hypogonadal
male patients. However, due to the varying effects on different as-
pects of the immune system (it is not likely that testosterone's anti‐
inflammatory effects would reduce all parts of immune function
equally) it would be necessary to look at testosterone effects on
various functions of both innate and adaptive immunity in a variety of
contexts to elucidate its therapeutic potential, as well as testosterone
deficiency in hypogonadism contribute to increase the risk of
comorbidities such as type 2 diabetes mellitus (T2DM), and cardio-
vascular diseases.101–103 Thus, increase the rate of ICU admissions
and mortality in COVID‐19 patients as Cayan S et al. suggests.101
Furthermore, a systemic review spotlights in the acute man-
agement of COVID‐19, T2DM and hypogonadism suggests that
treating testosterone deficient COVID‐19 patients with testosterone
might be considered in the future as Testosterone reduces the risk of
T2DM, and boosts the body inflammatory response against the virus
acutely.102 However, further studies required in order to reveal the
optimal effect of Testosterone replacement therapy.
4 | SEX AND GENDER RELATED RISK FACTORS
Clinical data has highlighted that specific comorbidities increase the
risk of COVID‐19 severity. Guan et al. (2020) showed that COVID‐19
patients with comorbidities have a poorer prognosis, and that greater
number of comorbidities correlate to poorer clinical outcomes.2
Specific comorbidities associated with poorer patient outcomes
included chronic obstructive pulmonary disease (COPD), Obesity,
diabetes, cerebrovascular disease, cancer and hypertension.2,102–104
Globally, men have more of these morbidities than women,105 placing
them at a higher risk for severe disease.
In addition to biological sex‐based differences, gender as defined
as the social and cultural norms, roles, attributes and behaviours that
society considers appropriate for males and females, is likely to play a
role in the incidence and fatality of COVID‐19. A meta‐analysis by
Zhao et al. (2020) which analysed data from 1726 patients showed
that smoking has a significant association with COVID‐19 severity,
with odds ratio of 2.0 (95%CI 1.3‐3.1).106 This observation has since
been confirmed by several studies that also reported increased disease
severity and death in COVID‐19 patients who smoke, potentially
related to higher expression of ACE2.107,108 Indeed, gender
differences in smoking rate between men and women has been sug-
gested to contribute to their predisposition to COVID‐19 progres-
sion.109 However, a male bias is often still observed in countries
reporting equal rates of current smokers between the genders, and
large variations across age and ethnicity confound this relationship
resulting in review of the current literature not supporting smoking as
a predisposing factor in men for COVID‐19 incidence or severity.109
Other gender‐based differences include delay in accessing health
services bymen that lead to higher fatality, as suggested from the data
of the Ebola outbreak.110 Furthermore, handwashing behaviour, which
is the primary public health message in this pandemic, also exhibits a
sex difference with women being more frequent adherers to guide-
lines.111 Therefore, understanding the sex differences in COVID‐19
severity and mortality requires recognition of both the biological and
the social factors that may play a role.
4.1 | Sex disparity in ‘long–COVID’
It is becoming evident that the impact of the SARS‐CoV‐2 pandemic is
likely to be much larger due to the long term persistence of symptoms
in patients following the initial acute stage. In a subset of COVID‐19
patients, a syndromic state post the acute symptomatic phase has
been reported which includes a wide range of symptoms such as
dyspnoea, extreme fatigue, tachycardia and mental fog.112–114 This
prolonged symptomatic phase (beyond 3‐weeks) is being referred to
as ‘Long‐COVID’, ‘Long‐haulers’ or ‘Chronic COVID Syndrome’, and is
still poorly understood.
A recent report describing data collected from over 4000 pa-
tients using a mobile application showed that symptoms persist for
28 days in 13% patients, of which 4.5% and 2.3% experienced
symptoms for 56 and 94 days respectively.115 The study also re-
ported that age significantly associated with long‐COVID, rising from
10% in 18–49 year olds, to 22% in those above 70. Interestingly, and
conversely to the acute phase, long‐COVID seems to affect women
disproportionately (14.9%) compared to men (9.5%), with females
aged 50–60 having the highest odds ratio, although this sex effect
was not significant in the older age‐group (>70).115 Whilst the aeti-
ology of the syndrome and reasons for any sex disparity needs
further research, a pre‐existing asthma condition, which is more
common in women, increased the odds of having long‐COVID.115,116
5 | CONCLUSION
The sex disparities in COVID‐19 severity and mortality are multi-
factorial, may also be resulted from the sex‐difference comorbidities
and behaviours, thus underline the need to collect sex and age‐dis-
aggregated data to better understand disease pathology and guide
clinical care. It has also highlights the need to incorporate sex and
gender analyses in any therapeutic strategies under consideration,
and vaccine development protocols. Furthermore, the consistencies
with previous coronavirus pandemics suggest that the public health
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policies and risk stratification should take sex into consideration for
any future outbreaks.
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